Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals has reported Other Non-Current Assets for 18 years, with the latest figure at $2.3 billion in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 50.06% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 50.06% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 60.32% from the prior year.
• Other Non-Current Assets was $2.3 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $2.1 billion in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.3 billion in Q2 2026, with the low at $262.0 million in Q1 2022.
• Average Other Non-Current Assets over 5 years is $960.5 million, with a median of $732.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets gained 28.01% in 2023, then surged 196.28% in 2025.
• Over 5 years, Other Non-Current Assets stood at $336.4 million in 2022, then jumped by 32.02% to $444.1 million in 2023, then jumped by 155.8% to $1.1 billion in 2024, then soared by 60.32% to $1.8 billion in 2025, then advanced by 26.63% to $2.3 billion in 2026.
• The last three Other Non-Current Assets figures came in at $2.3 billion (Q2 2026), $2.1 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.